Experienced in Essential Thrombocythemia

Dr. Kimberly R. Kruczek

Primary Healthcare Associates Sc
Flossmoor, IL
Experienced
in Essential Thrombocythemia
Specialties:Hematology Oncology | Hematology | Oncology
Accepting New Patients
Offers Telehealth
OverviewInsuranceLocationsClinical Research

Overview

Kimberly Kruczek is a Hematologist Oncology specialist and a Hematologist in Flossmoor, Illinois. Dr. Kruczek and is rated as an Experienced provider by MediFind in the treatment of Essential Thrombocythemia. Her top areas of expertise are Childhood Iron Deficiency Anemia, Paget Disease of the Breast, Lung Cancer, and Familial Prostate Cancer. Dr. Kruczek is currently accepting new patients.

Her clinical research consists of co-authoring 6 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in IL
Hospital Affiliations
Ingalls Memorial Hospital
The University Of Chicago Medical Center
Languages Spoken
English
Gender
Female

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Oscar
  •  Humana

Locations

PRIMARY HEALTHCARE ASSOCIATES SC
19550 Governors Hwy 3300, Flossmoor, IL 60422
708-915-8660

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Randomized Phase III Study of Immune Checkpoint Inhibition With Chemotherapy in Treatment-Naive Metastatic Anal Cancer Patients
A Randomized Phase III Study of Immune Checkpoint Inhibition With Chemotherapy in Treatment-Naive Metastatic Anal Cancer Patients
Enrollment Status: Active_not_recruiting
Publish Date: February 06, 2025
Intervention Type: Biological, Drug
Study Drugs: Carboplatin, Nivolumab, Paclitaxel
Study Phase: Phase 3
CASPAR - a Phase III Trial of Enzalutamide and Rucaparib As a Novel Therapy in First-Line Metastatic Castration-Resistant Prostate Cancer
CASPAR - a Phase III Trial of Enzalutamide and Rucaparib As a Novel Therapy in First-Line Metastatic Castration-Resistant Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 15, 2025
Intervention Type: Other, Drug
Study Drugs: Enzalutamide, Rucaparib Camsylate, Leuprolide Acetate, Goserelin Acetate, Degarelix
Study Phase: Phase 3
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: January 14, 2025
Intervention Type: Drug
Study Drug: Tisotumab Vedotin
Study Phase: Phase 2
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Drug
Study Drugs: Palbociclib, Trastuzumab, Pertuzumab, Letrozole, Anastrozole, Exemestane, Fulvestrant
Study Phase: Phase 3
A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: January 03, 2025
Intervention Type: Drug, Biological, Procedure, Other, Radiation
Study Drugs: Brentuximab, Dacarbazine, Doxorubicin, Filgrastim, Nivolumab, Pegfilgrastim, Vinblastine
Study Phase: Phase 3
Single Arm, Open Label Phase 1b/2 Study of SGN-LIV1A in Combination With Pembrolizumab for First-Line Treatment of Patients With Unresectable Locally-Advanced or Metastatic Triple-Negative Breast Cancer
Single Arm, Open Label Phase 1b/2 Study of SGN-LIV1A in Combination With Pembrolizumab for First-Line Treatment of Patients With Unresectable Locally-Advanced or Metastatic Triple-Negative Breast Cancer
Enrollment Status: Completed
Publish Date: December 20, 2024
Intervention Type: Drug
Study Drugs: ladiratuzumab vedotin, Pembrolizumab
Study Phase: Phase 1/Phase 2
View 5 Less Clinical Trials

6 Total Publications

Sole rearrangement but not amplification of MYC is associated with a poor prognosis in patients with diffuse large B cell lymphoma and B cell lymphoma unclassifiable.
Sole rearrangement but not amplification of MYC is associated with a poor prognosis in patients with diffuse large B cell lymphoma and B cell lymphoma unclassifiable.
Journal: British journal of haematology
Published: May 25, 2016
Similar Doctors
Expertise in
29
conditions
Dr. Brady L. Stein
Hematology
Expertise in
29
conditions
Dr. Brady L. Stein
Hematology

Northwestern Medical Faculty Foundation

250 E Superior St, 
Chicago, IL 
 (25.3 mi)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Brady Stein is a Hematologist in Chicago, Illinois. Dr. Stein and is rated as an Elite provider by MediFind in the treatment of Essential Thrombocythemia. His top areas of expertise are Polycythemia Vera, Myelofibrosis, Myeloproliferative Neoplasms (MPN), and Essential Thrombocythemia. Dr. Stein is currently accepting new patients.

Damiano Rondelli
Expertise in
19
conditions
Dr. Damiano Rondelli
Hematology Oncology | Rheumatology | Hematology
Expertise in
19
conditions
Dr. Damiano Rondelli
Hematology Oncology | Rheumatology | Hematology

The Board Of Trustees Of The University Of Illinois

1855 W Taylor St, Mc648, 
Chicago, IL 
 (23.2 mi)
312-996-6590
Languages Spoken:
English, Italian

Damiano Rondelli is a Hematologist Oncology specialist and a Rheumatologist in Chicago, Illinois. Dr. Rondelli and is rated as a Distinguished provider by MediFind in the treatment of Essential Thrombocythemia. His top areas of expertise are Sickle Cell Disease, Polycythemia Vera, Myelofibrosis, Bone Marrow Transplant, and Bone Marrow Aspiration.

Expertise in
23
conditions
Dr. John G. Quigley
Hematology Oncology | Hematology | Oncology
Expertise in
23
conditions
Dr. John G. Quigley
Hematology Oncology | Hematology | Oncology

The Board Of Trustees Of The University Of Illinois

1740 W Taylor St, 
Chicago, IL 
 (23.2 mi)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

John Quigley is a Hematologist Oncology specialist and a Hematologist in Chicago, Illinois. Dr. Quigley and is rated as a Distinguished provider by MediFind in the treatment of Essential Thrombocythemia. His top areas of expertise are Acute Myeloid Leukemia (AML), Essential Thrombocythemia, Multiple Myeloma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Quigley is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile